GMJ Medicine

en Comparison of Ondansetron and Metoclopramide in Prevention of Nausea and Vomiting after Coronary Artery Bypass Graft Surgery Original Research Aims: The aim of this study was to determine the effect of ondansetron and metoclopramide on the prevention of PONV in high-risk patients. The reason for choosing these two drugs is that ondansetron is a drug that is widely used in the world today as a first-line drug in the prevention and treatment of PONV, and metoclopramide is a drug that is cheap and available as a common anti-emetic drug by surgeons PONV control is prescribed in Iran. Materials & Methods: A total of 126 patients who were candidates for coronary artery bypass graft surgery during 2018 and 2019 were evaluated in this study. Intraoperative injection of metoclopramide or ondansetron was compared between all patients and the severity of postoperative nausea and vomiting was compared. Findings: The rate of nausea in patients was about 67.5% with an average of 158.5 seconds of nausea in these patients each day and there was no significant difference between the two drug groups in terms of these two variables (p=0.342; p=0.900). The average rate of vomiting in patients was 19.8%, of which 52% had vomiting once and 48% had vomited more than once. There was a significant difference in the presence of vomiting in the two drug groups (p=0.044). Conclusion: Metoclopramide and Ondansetron have the similar effects on nausea and vomiting after coronary artery bypass graft surgery.   Metoclopramide, Ondansetron, PONV, CABG 97 100 http://gmedicine.de/browse.php?a_code=A-10-1-25&slc_lang=en&sid=2 H. Mohammadipour Anvari 10031947532846001380 10031947532846001380 Yes Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran S. Sadeghi 10031947532846001381 10031947532846001381 No Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran